Core Insights - Illumina Inc. reported fourth-quarter 2025 adjusted EPS of $1.35, exceeding the Zacks Consensus Estimate by 7.4% and reflecting a year-over-year increase of 42.1% [1] - The company's GAAP EPS was $2.16, significantly higher than 73 cents a year ago [1] - Full-year adjusted EPS reached $4.84, marking a 16.3% increase year over year [1] Revenue Performance - Fourth-quarter revenues were $1.16 billion, up 5.4% year over year and slightly above the Zacks Consensus Estimate by 0.3% [2] - Full-year revenues totaled $4.34 billion, a modest increase of 0.2% year over year, remaining flat on a constant-currency basis [2] - Following the earnings announcement, Illumina's shares fell by 10.4%, attributed to concerns over gross margin contraction [2] Segment Analysis - Revenues from the Product segment amounted to $990 million, reflecting a 5.4% year-over-year increase [3] - Services and other revenues were $169 million, up 2.4% year over year [3] Margin Analysis - The adjusted gross margin was 65.5%, down 45 basis points year over year due to a 6.4% increase in the cost of revenues [4] - Research and development expenses decreased by 6.6% year over year to $239 million, while SG&A expenses totaled $310 million, down 11.1% from the previous year [4] - Adjusted operating margin expanded by 64 basis points to 63.7% [4] Financial Position - At the end of the fourth quarter of 2025, Illumina had cash and cash equivalents of $1.42 billion, up from $1.13 billion at the end of the fourth quarter of 2024 [5] - Cumulative net cash provided by operating activities was $1.08 billion, compared to $837 million a year ago [5] Future Guidance - For 2026, Illumina expects total revenues to be in the range of $4.50 billion to $4.60 billion, indicating growth of 4-6% on a reported basis [6] - The Zacks Consensus Estimate for 2026 revenues is currently at $4.54 billion [6] - Non-GAAP diluted EPS is projected to be between $5.05 and $5.20 in 2026, with the Zacks Consensus Estimate for full-year EPS at $5.14 [9] Strategic Developments - Notable developments in the quarter included the acquisition of SomaLogic and the launch of the Billion Cell Atlas, aimed at supporting AI-enabled drug discovery [10]

Market Overview - February has started with a subdued market sentiment, characterized by an AI-driven sell-off in U.S. stocks as investors reassess high expectations [1] - Concerns have emerged regarding the potential erosion of pricing power for software stocks due to AI tools, alongside fears of a slowdown in hyperscaler AI capital expenditures impacting chip and data-center suppliers [1] - The market is seeking clearer monetization strategies and disciplined spending from companies [1] Investment Recommendations - Retail investors may find it challenging to identify stocks for solid long-term returns, but following broker recommendations can simplify this process [2] - Stocks such as Jacobs Solutions Inc. (J), Envista Holdings Corporation (NVST), and Tapestry, Inc. (TPR) are highlighted as potential investment opportunities [2] Broker Insights - Brokers develop informed views by engaging with senior management, analyzing public disclosures, and participating in earnings calls, which helps contextualize a company's fundamentals within the broader economic landscape [3] - Upgrades from brokers are often based on new evidence, such as updated guidance or channel checks, which can indicate an inflection point before it is reflected in market consensus [4] Stock Screening Strategy - A screening strategy is proposed to identify potential winning stocks, focusing on those with broker rating upgrades of 1% or more over the past four weeks [6] - Stocks must have a current price greater than $5 and an average 20-day trading volume exceeding 100,000 to ensure liquidity [6] Specific Stock Performances - Jacobs Solutions is expected to see a 16.5% year-over-year increase in fiscal 2026 earnings and has experienced a 6.3% upward revision in broker ratings recently [9] - Envista Holdings, with a diversified portfolio in dental solutions, is projected to have a 17.7% increase in earnings for 2026 and has seen an 18.5% upward revision in broker ratings [10] - Tapestry is anticipated to achieve a 19% year-over-year earnings growth in fiscal 2026, with a 5% increase in broker ratings [11]

Core Insights - Edwards Lifesciences Corporation reported fourth-quarter 2025 adjusted earnings per share (EPS) of 58 cents, missing the Zacks Consensus Estimate by 5.89% and reflecting a 1.7% year-over-year decline [1] - Full-year adjusted EPS was $2.56, a 5.3% increase from 2024, but also missed the Zacks Consensus Estimate by 1.2% [2] Revenue Performance - Total sales for the fourth quarter reached $1.57 billion, marking a 13.3% year-over-year increase and surpassing the Zacks Consensus Estimate by 1.99% [3] - Full-year revenues for 2025 amounted to $6.07 billion, up 11.5% year over year, also beating the Zacks Consensus Estimate by 0.7% [3] Segment Sales Analysis - Transcatheter Aortic Valve Replacement (TAVR) sales were $1.16 billion, up 12% year over year, driven by increased focus on SAPIEN therapy [4] - Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reached $155.7 million, a significant 48.3% increase from the prior year, exceeding projections [5] - Surgical Structural Heart sales totaled $253.6 million, reflecting a 3.8% year-over-year growth despite some inventory adjustments [6] Margin and Cost Analysis - Gross profit was $1.22 billion, a 12.2% increase year over year, but gross margin contracted by 77 basis points to 78.2% due to a 17.4% rise in cost of sales [7] - Selling, General and Administrative (SG&A) expenses rose 22.6% year over year to $602.9 million, while R&D expenditures decreased by 1.3% to $267.7 million [7] Future Guidance - For 2026, the company projects sales growth of 8% to 10%, with adjusted EPS expected in the range of $2.90 to $3.05 [11] - The first quarter of 2026 is projected to have total sales between $1.55 billion and $1.63 billion, with adjusted EPS in the range of 70 to 76 cents [12] Overall Performance Summary - Despite an earnings miss, Edwards Lifesciences experienced revenue growth and expressed confidence in its 2026 outlook, supported by strong quarterly performance and ongoing adoption of its therapies [13]

Core Insights - CVS Health Corporation reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.09, an 8.4% decline year over year, but exceeded the Zacks Consensus Estimate by 10.1% [1][9] - The company's total revenues for the fourth quarter rose 8.2% year over year to $105.69 billion, surpassing the Zacks Consensus Estimate by 2.2% [3][9] - CVS Health's full-year adjusted EPS was $6.75, a 24.5% increase from 2024, beating the Zacks Consensus Estimate by 1.5% [2] Revenue Performance - Health Services revenues increased 9% year over year to $51.24 billion, driven by pharmacy drug mix and brand inflation, despite a 7.5% decline in total pharmacy claims processed [4] - Revenues in the Pharmacy & Consumer Wellness segment rose 12.4% year over year to $37.66 billion, primarily due to increased prescription volume and acquisitions, offset by reimbursement pressure [5] - The Health Care Benefits segment reported revenues of $36.29 billion, up 10.1% year over year, largely due to the Government business and the Inflation Reduction Act's impact on Medicare Part D [6] Margin Analysis - The combined cost of products sold and healthcare costs rose 8.6% to $92.13 billion, while gross profit increased 5.2% to $13.57 billion, leading to a gross margin contraction of 37 basis points to 12.8% [7] - Adjusted operating margin contracted 44 basis points to 1.9%, despite an 8.9% rise in total operating expenses to $11.46 billion [7] Liquidity Position - CVS Health ended 2025 with cash and cash equivalents of $8.45 billion, a slight decrease from $8.59 billion at the end of 2024, while long-term debt increased to $64.57 billion from $64.15 billion [8] Future Guidance - CVS Health provided 2026 adjusted EPS guidance in the range of $7.00-$7.20, with the Zacks Consensus Estimate currently at $7.15 [11] Overall Assessment - CVS Health's fourth-quarter earnings and revenues exceeded estimates, with year-over-year revenue growth across all segments. However, higher costs and expenses led to margin contraction and bottom-line pressure [12]

Core Insights - Zimmer Biomet Holdings, Inc. (ZBH) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.42, exceeding the Zacks Consensus Estimate by 1.7% and reflecting a year-over-year increase of 4.8% [1] - The company achieved net sales of $2.24 billion for the quarter, a 10.9% increase year over year, surpassing the Zacks Consensus Estimate by 1.9% [3] - Full-year adjusted EPS was $8.20, marking a 2.5% increase year over year and slightly beating the Zacks Consensus Estimate by 0.5% [2] Revenue Performance - ZBH's net sales for the full year reached $8.23 billion, a 7.2% increase year over year, also marginally exceeding the Zacks Consensus Estimate by 0.5% [3] - U.S. sales totaled $1.31 billion for the quarter, up 11.11% year over year, while international sales were $931.2 million, reflecting a 10.6% increase year over year [4] - Revenue growth was observed across all four product categories, with the S.E.T. unit experiencing a notable 20.1% increase year over year at constant currency [5] Margin Analysis - Adjusted gross margin was reported at 64.7%, a contraction of 632 basis points year over year, primarily due to a 35.1% rise in the cost of products sold [7] - Selling, general and administrative expenses rose 16.8% to $872.3 million, while research and development expenses increased by 9.6% to $118.8 million [7] - Adjusted operating margin contracted 821 basis points to 20.5% [7] Cash Position - At the end of the fourth quarter, ZBH had cash and cash equivalents of $591.9 million, an increase from $525.5 million at the end of the fourth quarter of 2024 [9] - Cumulative net cash provided by operating activities was $1.70 billion, up from $1.50 billion in the previous year [9] Future Outlook - For 2026, ZBH expects revenue growth in the range of 2.5-4.5%, with the Zacks Consensus Estimate for revenues at $8.41 billion, indicating a 3.1% year-over-year growth [10] - Adjusted EPS guidance for the full year is projected to be between $8.30 and $8.45, with the Zacks Consensus Estimate for 2025 adjusted EPS at $8.54 [10] Overall Assessment - ZBH's fourth-quarter results exceeded expectations, with growth reported across all business segments [11] - Notable developments contributing to growth include FDA clearance for ROSA Knee and the launch of the Brachiator Mini-Rail External Fixation System [11] - Despite the positive revenue and earnings performance, the contraction in margins presents a concern [11]

Core Insights - Quest Diagnostics Inc. reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.42, exceeding the Zacks Consensus Estimate by 2.85% and up 8.5% year-over-year [1][2] - The company’s full-year 2025 adjusted EPS was $9.85, reflecting a 10.3% increase from the previous year and surpassing the Zacks Consensus Estimate by 0.5% [2] Revenue Performance - Fourth-quarter revenues increased by 7.1% year-over-year to $2.81 billion, beating the Zacks Consensus Estimate by 2.08% [3][4] - Diagnostic Information Services revenues rose 7.3% year-over-year to $2.74 billion, with requisition volumes up 8.5% [3][7] Margin Analysis - The cost of services for the quarter was $1.90 billion, a 7.5% increase year-over-year, while gross profit was $910 million, up 6.1% [5] - The gross margin decreased by 30 basis points to 32.4%, and the adjusted operating margin contracted by 49 basis points to 14.5% [5][10] Financial Position - At the end of the fourth quarter of 2025, cash and cash equivalents were $420 million, down from $549 million at the end of 2024 [6] - Cumulative net cash from operating activities was $1.89 billion, an increase from $1.33 billion at the end of 2024 [6] 2026 Guidance - For full-year 2026, revenues are projected to be between $11.70 billion and $11.82 billion, indicating a year-over-year growth of 6% to 7.1% [7][8] - Adjusted EPS is expected to be in the range of $10.50 to $10.70, with the Zacks Consensus Estimate at $10.45 [8] Strategic Execution - The company has focused on deploying AI and automation across its systems and has introduced innovations in its Advanced Diagnostics portfolio [10] - Quest Diagnostics achieved 3% annual cost savings and productivity improvements through its Invigorate program [10]

Group 1: Envista (NVST) - Envista is a global family of over 30 dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr [1] - The company has a Zacks Rank of 1 (Strong Buy) and its current year earnings estimate increased by 8.8% over the last 60 days [1] - Envista's shares gained 45.1% over the last three months, significantly outperforming the S&P 500's gain of 1.3% [2] - The company possesses a Momentum Score of A [2] Group 2: Banco Bilbao Viscaya Argentaria (BBVA) - Banco Bilbao Viscaya Argentaria is engaged in a variety of banking and financial activities in Spain [2] - The company has a Zacks Rank of 1 and its current year earnings estimate increased by 17.7% over the last 60 days [2] - BBVA's shares gained 14.2% over the last three months, also outperforming the S&P 500's gain of 1.3% [3] - The company possesses a Momentum Score of A [3] Group 3: Plexus (PLXS) - Plexus is a leading provider of electronic contract manufacturing services to OEMs across various industries, including Healthcare/Life Sciences, Industrial, and Aerospace/Defense [4] - The company has a Zacks Rank of 1 and its current year earnings estimate increased by 1.6% over the last 60 days [4] - Plexus' shares gained 41.2% over the last three months, outperforming the S&P 500's gain of 1.3% [5] - The company possesses a Momentum Score of A [5]

Core Viewpoint - BofA analyst Allen Lutz has raised the price target for Envista (NVST) to $32 from $28 while maintaining a Buy rating on the shares, indicating a positive outlook for the company following its earnings report [1]. Revenue and EBITDA Estimates - The firm is increasing FY26 revenue and EBITDA estimates due to modestly better organic growth and a favorable foreign exchange tailwind, suggesting improved financial performance for Envista [1].

Core Insights - Envista Holdings Corp. (NYSE:NVST) experienced a significant stock price increase of 23.4% week-on-week, reaching a nearly three-year high, driven by strong earnings performance and a return to profitability [1][3] Financial Performance - The company reported a net income of $47 million for the previous year, a turnaround from a net loss of $1.1 billion in 2024 [3] - Year-on-year sales increased by 8% to $2.7 billion, up from $2.5 billion [3] - In Q4, net profit surged by 2,642% to $32.9 million from $1.2 million in the same quarter the previous year [3] - Q4 sales grew by 15% to $750.6 million, compared to $652.9 million in the same period last year [3] Strategic Focus - The CEO emphasized a disciplined focus on growth, operations, and employee development, highlighting positive growth across all major businesses and geographies [4] - The company returned $166 million to shareholders through share repurchases [4] Future Outlook - For the current year, Envista aims to grow core sales by 2 to 4% and expects adjusted EBITDA to increase by 7 to 13% [5] - Adjusted diluted earnings per share are projected to be between $1.35 and $1.45 [5]

Core Insights - Envista reported broad-based growth in Q4 2025, with core sales increasing by 10.8% and full-year sales reaching $2.7 billion, reflecting a 6.5% increase year-over-year [4][6][5] - The company emphasized its Value Creation Plan, focusing on growth, operations, and people, with medium-term financial objectives of 2%-4% core growth, 4%-7% EBITDA growth, and 7%-10% EPS growth [3][4] - Management highlighted significant cost reductions, with G&A spending down by over $35 million in 2025, and a $250 million share repurchase program initiated [1][4] Financial Performance - Full-year adjusted EBITDA margin improved to 13.7%, a 190 basis point increase from 2024, while adjusted EPS rose to $1.19, up $0.46 year-over-year [14] - Free cash flow for 2025 was reported at $231 million, with a conversion rate of 114% [14] - Q4 sales were reported at $751 million, with foreign exchange contributing nearly 400 basis points to growth [8][10] Growth Drivers - All business segments delivered positive growth, with notable contributions from new product introductions and increased clinical training, resulting in nearly $100 million in revenue from products launched in the last year [2][4] - The company trained 30% more customers in 2025, which contributed to accelerating growth [2] - New product launches included major introductions in Spark and diagnostics, with plans for further launches in 2026 [7][4] Market Outlook - For 2026, Envista guided core sales growth of 2%-4%, adjusted EBITDA growth of 7%-13%, and adjusted EPS between $1.35 and $1.45 [18] - Management expects the dental market to remain stable with potential for modest improvement, while also noting calendar effects that may impact quarterly growth [19] - The company anticipates a $30 million headwind from tariffs in 2026, with strategies in place to offset this through pricing and cost reductions [20] Segment Performance - Specialty Products & Technologies saw revenue growth of nearly 16% year-over-year, with core sales up 10.9% [16] - Equipment and Consumables reported core sales growth of 10.7%, with diagnostics achieving double-digit growth globally [17] - Adjusted operating margins in Specialty Products & Technologies improved significantly, while Equipment and Consumables faced margin declines due to investments for future growth [16][17]